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Background: Although HPV vaccination has been recommended for use in girls and young women since
2007, HPV vaccine uptake is low in the US.
Methods: We conducted a retrospective cohort study using the 2008–2011 MarketScan data to examine
HPV vaccine completion and dose adherence among commercially insured females aged 9–26 years. We
performed multivariable logistic regression models to examine factors related to HPV vaccine completion
and HPV vaccine dose adherence.
Results: Among 378,484 females aged 9–26 years who initiated HPV vaccination, only 29.4% completed
HPV vaccination. Compared with females receiving vaccines from primary care providers, those receiving
vaccines from OB/GYN providers were more likely to complete the vaccine series. Age at HPV vaccine
initiation, health insurance plan, seasonal pattern, and ﬂu vaccination were also signiﬁcantly associated
with vaccine completion. Among 111,286 females who completed HPV vaccination, 62.4% received all
doses within 30 days of the recommended schedules. Similar factors relating to HPV vaccine completion
were consistently associated with HPV vaccine dose adherence. However, younger age (o22 years) and
receipt of ﬂu vaccine were negatively related to HPV vaccine dose adherence.
Conclusions: Intervention programs to improve HPV vaccine reminding system and reduce logistic bar-
riers for both physicians and patients are warranted.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Human papillomavirus (HPV) infection is an established causal
factor associated with about 5% of all human cancers, including
cervical, anogenital and oropharyngeal cancers [1,2]. In the United
States (US), about 34,000 HPV-related cancers are diagnosed
annually and medical expenses for preventing and treating HPV-
related diseases are estimated to be $8 billion every year [3,4]. HPV
vaccination has been advocated as a safe and effective strategy for
preventing HPV-associated cancers that are caused by vaccine-
covered types [5–8]. A signiﬁcant decline in prevalence of HPV16,
18, 6, and 11 has been observed in adolescent girls aged 14–19
years and no serious safety concerns have been detected following
HPV vaccine introduction in 2006 [8–11]. Therefore, HPV vacci-
nation is included in the U.S. Department of Health and Human
Services Healthy People 2020 (HP2020) with a national objective
of 80% 3-dose coverage rate for females by age 13–15 years [12].B.V. This is an open access article u
Health Sciences, Penn State
ershey, PA 17033-0855, USA.Despite scientiﬁc evidence and strong recommendations, HPV
vaccination in the US remains well below the HP2020 objective;
the 3-dose coverage rate is only 39.7% among adolescent girls aged
13–17 years in 2014, and gaps exist in receiving all three doses
within recommended schedules [13–15]. Because the overall
effectiveness of HPV vaccination on reducing HPV-related diseases
would be affected by a delayed or incomplete vaccination, imm-
ediate and multi-level actions are urged by the President Cancer
Panel to increase HPV vaccine uptake as a national public health
priority in the US [16].
In order to improve HPV vaccination, it is essential to under-
stand current patterns of HPV vaccination. While previous rese-
arch has primarily focused on HPV vaccine initiation and com-
pletion among adolescent girls, the adherence of recommended
HPV dose schedules has not been well assessed [17–22]. The
objectives of this study were to: (1) examine HPV vaccine com-
pletion and dose adherence among commercially insured females
who were aged 9 through 26 years old and had initiated HPV
vaccination; (2) identify factors associated with HPV vaccine
completion and dose adherence among these females. Our work
will provide insights on compliance of HPV vaccine guidelines in
the real-world context and shed lights on the potential areasnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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insurance companies and policy makers can contribute to enhance
HPV vaccination in the US.Materials and methods
Data source
We conducted a retrospective cohort study using the national
health insurance claims data, the 2008–2011 MarketScan Com-
mercial Claims and Encounters (CCE) database [23]. The Market-
Scan CCE database consists of reimbursed health care claims for
employees, retirees, and their dependents of over 250 medium
and large employers nationwide. Individuals included in the
database are covered under commercial (private) insurance plans
(Medicaid or Medicare data are not included). The database
includes claims information from more than 130 payers, and
describes the health care service use and expenditures for more
than million covered individuals each year. We identiﬁed events of
HPV vaccination from the in-patient and out-patient claims based
on the Current Procedural Terminology 4th Edition [CPT-4] codes
(90649 for Gardasil and 90650 for Cervarix) and linked multiple
claims of HPV vaccination for each individual using a unique
identiﬁer (Enrollee ID). We also obtained information on indivi-
dual’s age, gender, geographic location (US census region and
state), type of health insurance plan, date(s) of HPV vaccination,
receipt of seasonal ﬂu vaccine, and type of provider who admi-
nistered HPV vaccines.
Study population
To deﬁne a cohort of females who newly initiated HPV vacci-
nation, we focused on females aged 9 through 26 years who had at
least one claim of HPV vaccination during the period from 2009–
2010 and had no claims of vaccination in 2008. We used the date
of the ﬁrst HPV vaccination claim in 2009–2010 as the index date
and included females who had been continuously enrolled in an
insurance plan from 12 months prior to the index date to 12
months post the index date to ascertain all HPV vaccination claims
within 12 months. We chose the 12-month period for HPV vacci-
nation because evidence indicated that 3 doses of HPV vaccine
received within 12 months produced comparable immunogenicity
compared to the standard 6-month HPV vaccination, but HPV
vaccination with longer than a 12-month interval did not meet the
non-inferiority criteria [24]. We excluded 1987 females with more
than 3 HPV vaccination claims during this study period because
we cannot verify if receipt of 43 doses is due to re-initiation of
HPV vaccine series or a coding error. We also excluded 125,362
females who had HPV vaccination claims in 2008 because we did
not have the 2006–2007 data to conﬁrm the HPV vaccine
initiate date.
Statistical analysis
We examined two dichotomous outcomes: (1) completion of
HPV vaccination within 12 months among females who had
initiated HPV vaccination in 2009–2010, which was deﬁned as
‘Yes’ for those who received all 3 doses of HPV vaccines and ‘No’
for those who had 1 or 2 doses in a 12-month period; (2) adher-
ence of recommended HPV vaccine dose schedules, which was
determined by intervals between two consecutive HPV doses
recommended by the Advisory Committee on Immunization
Practices (ACIP) [8]. If an individual ﬁnished both the 2nd and 3rd
doses of HPV vaccines no later than 30 days after the recom-
mended interval, we considered the adherence as “Yes” (otherwise“No” if either dose was delayed). For Gardasil it is recommended
that the 2nd and the 3rd doses to be completed at the end of the
2nd and 6th month; and for Cervarix, it is recommend that the
2nd and the 3rd doses be completed at the end of the 1st and 6th
month. We deﬁned the adherence intervals as within 90 days and
60 days after the date of the 1st dose for the 2nd dose of Gardasil
and Cervarix, respectively, and within 210 days after the 1st dose
for the 3rd dose of both Gardasil and Cervarix.
We calculated descriptive statistics, including the percentage,
median and mean to depict the overall pattern of HPV vaccination.
We examined HPV vaccine completion and dose adherence stra-
tiﬁed by individuals’ characteristics (age at the 1st dose of HPV
vaccination, US census region, urban or rural residence based on
the Metropolitan Statistical Area [MSA] code, health insurance
plan, type of provider who administered the 1st dose of HPV
vaccine series, ﬂu vaccination during the study period, and quarter
of the year of HPV vaccine initiation). We evaluated the associa-
tions using the t test for continuous variables and the χ2 test or
Fisher exact test for categorical variables. We then performed
multivariable logistic regression models to identify factors that
were signiﬁcantly associated with the study outcomes (two-sided
P-value o0.05) and reported adjusted odds ratios (aOR) and their
95% conﬁdence intervals (CI). We conducted all statistical analyses
using SAS version 9.3 (SAS Institute, Cary, NC). Given the very large
sample size from claims data, there is tremendous statistical
power to detect very small effect sizes. Therefore, the interpreta-
tions of statistically signiﬁcant results need to take into account
the practical implications in terms of odds ratios.Results
A total of 378,484 commercially insured females aged 9–26
years were included in this study, and the majority (99.2%)
received the quadrivalent HPV vaccine (Gardasil, Merck & Co Inc,
Whitehouse Station, New Jersey). Fig. 1 presented the cohort
characteristics by age group at the 1st dose of HPV vaccination,
geographic region, health insurance plan, and type of provider
who administered the 1st dose of HPV vaccine series. Pre-
adolescent girls aged 9–12 years accounted for 24.2% of the
entire study population. The cohort represented four census
regions with 37.8% from South, 27.2% from North Central, 19.7%
from West and 15.3% from Northeast. Most people (88.7%) lived in
the MSA (urban) and only 11.3% lived outside an MSA (rural). The
majority had either preferred provider organization (PPO) health
plan (65.8%) or health maintenance organization (HMO) plan
(16.5%). Consistent with the age distribution, over 70% of females
received vaccines from pediatricians (42.8%), non-pediatric pri-
mary care providers (14.3%), or obstetrics and gynecology (OB/
GYN) providers (13.1%), while the rest (29.8%) received from other
types of providers.
Fig. 2 showed the age distribution at the 1st dose of HPV vac-
cination. The mean age was 15.8 (standard deviation¼4.0), a
noticeable delay in initiating HPV vaccination according to the
ACIP recommendation. Fig. 3 presented a snapshot of HPV vaccine
completion and dose schedule adherence patterns in our study
cohort. In particular, among females who had initiated HPV vac-
cination, 43.8% had only one dose, and 56.2% received Z2 doses
(29.4% received all 3 doses). Among 111,286 females who com-
pleted the 3-dose vaccine series, 62.4% (about 18% of the study
population) had received both the 2nd and the 3rd doses within
30 days of the ACIP recommended intervals; 2.8% were late for the
2nd dose only; 21.7% were late for the 3rd dose only; and 13.2%
were late for both doses. Fig. 4a and b indicated great variations in
HPV vaccine completion and dose adherence across states. The
state-level HPV vaccine completion rates ranged from 15.7% in the
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Fig. 1. Characteristics of commercially insured females who were aged 9 through 26 years and had at least one claim of HPV vaccination during 2009–2010 (N¼378,484).
Footnotes: Health insurance plan that covers HPV vaccination: CDHP: consumer-driven health plan; EPO: Exclusive provider organizations; HDHP: high-deductible health
plan; POS: point of service; PPO: Preferred provider organizations; HMO: Health maintenance organizations; Other: Comprehensive and POS capitation. Provider type
represented providers who administered the 1st dose of HPV vaccine series. OB/GYN: obstetrics and gynecology.
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Fig. 2. Distribution of age at the 1st dose of HPV vaccination among 378,484
commercially insured females who were aged 9 through 26 years and had at least
one claim of HPV vaccination during 2009–2010.
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Fig. 3. HPV vaccine completion among 378,484 commercially insured females who
were aged 9 through 26 years and had at least one claim of HPV vaccination during
2009–2010 and HPV vaccine dose schedule adherence among 111,286 females who
completed the 3-dose HPV vaccine series.
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rates were lower than 60% in 14 states.
Factors associated with HPV vaccine completion
We presented the vaccine completion rates stratiﬁed by dif-
ferent factors (Table 1). Univariate analysis results showed that
vaccine completion was signiﬁcantly associated with age at the 1st
dose of HPV vaccination, geographic region, urban–rural residence,
health insurance plan, type of provider who administered the 1st
dose of HPV vaccine series, quarter of the year when the 1st dose
of vaccine was administered, and whether the patient also had ﬂu
vaccination during the study period, with all p-valueso0.0001,
except the p-value¼0.0408 for urban–rural residence.Pre-adolescents had the highest vaccine completion, while the
18–21 age group had the lowest rate (26.0%). Geographic variation
was also observed in HPV vaccine completion: the Northeast
region had the highest completion rate (33.1%), followed by North
central (31.3%); while the South and West regions had lower
completion rates (28.2% and 26.3%, respectively).
HPV vaccine completion rates varied across types of health
insurance plan as well as providers who administered the 1st dose
of vaccines. In particular, among adult females aged 22–26 years,
those with vaccine initiated by OB/GYN providers had a higher
completion rate (34.4% versus 26.8% for patients with vaccine
initiated by other providers in the 22–26 age group). Similarly at
the entire cohort level, females initiated HPV vaccines by OB/GYN
Fig. 4. a. State-level HPV vaccine completion rate among 378,484 commercially insured females who were aged 9 through 26 years and had at least one claim of HPV
vaccination during 2009–2010 Fig. 4b. State-level HPV vaccine dose schedule adherence rate among 111,286 females who completed the 3-dose HPV vaccine series.
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did clients of pediatricians (28.6%), primary care providers (29.2%),
and other specialists (27.6%).
We also observed a correlation between HPV vaccine comple-
tion and quarter of the year when the 1st dose of vaccine was
administered. In particular, the April–June quarter has the best
completion rate at 33.8%, while all other three quarters have rates
below 30%. Our results also showed that 34.7% of whom received
ﬂu vaccination completed HPV vaccine series, compared to only
26.5% among those who did not get ﬂu vaccination during the
study period.
The multivariable Logistic regression results indicated that all
factors found signiﬁcant in the bivariate analysis (i.e. age, census
region, health plan, provider type, ﬂu vaccination, and quarter of
the year) remained signiﬁcantly associated with HPV vaccinecompletion. In particular, compared to the 22–26 age group, the
18–21 age group had the lowest odds of completion (aOR¼0.90,
95% C.I.¼0.88,0.93), while the 11–12 age group had the highest
odds (aOR¼1.36, 95% C.I.¼1.32,1.40). Regarding geographic var-
iation, the completion rate seemed higher in Northeast region,
but was signiﬁcantly lower in the South and West regions
(South: aOR¼0.83, 95% C.I.¼0.81,0.84; West: aOR¼0.79, 95% C.
I.¼0.78,0.81). Compared with HPV vaccination initiated by pri-
mary care providers, clients of pediatricians corresponded to the
lowest odds of HPV vaccine completion (aOR¼0.85, 95% C.
I.¼0.83,0.87), but vaccine initiation by OB/GYN providers was
associated with higher odds of completion. Subgroup analyses
stratiﬁed by age (9–10, 11–-12, 13–15, 16–17, 18–21 and 22–26)
consistently showed the same patterns relating to providers across
all the pertinent age groups.
Table 1
HPV vaccine completion rate among 378,484 commercially insured females who were aged 9 through 26 years and had at least one claim of HPV vaccination during 2009–
2010 (N¼378,484)
Characteristics HPV vaccine completion N, % Multivariable logistic regression model
Adjusted OR 95% CI P-value
Age group at the 1st dose of HPV vaccination
9–10 (N¼7358) 2,416, 32.8% 1.34 1.26 1.41 o .0001
11–12 (N¼84,046) 27,041, 32.2% 1.36 1.32 1.40 o .0001
13–15 (N¼111,947) 32,790, 29.3% 1.19 1.15 1.22 o .0001
16–17 (N¼65,660) 18,741, 28.5% 1.12 1.09 1.16 o .0001
18–21 (N¼67,838) 17,667, 26.0% 0.90 0.88 0.93 o .0001
22–26 (N¼41,635) 12,631, 30.0% Ref.
US census region
Northeast (N¼58,035) 19,227, 33.1% 1.07 1.05 1.09 o .0001
South (N¼143,070) 40,307, 28.2% 0.83 0.81 0.84 o .0001
West (N¼74,409) 19,570, 26.3% 0.79 0.78 0.81 o .0001
North Central (N¼102,970) 32,182, 31.3% Ref.
Residence
Urban (MSA) (N¼335,670) 98,879, 29.5% 1.03 1.01 1.05 0.0146
Rural (non-MSA) (N¼42,814) 12,407, 29.0% Ref.
Health insurance plan
CDHP (N¼15,605) 5,291, 33.9% 1.25 1.21 1.30 o .0001
Comprehensive (N¼3703) 1,053, 28.4% 0.96 0.89 1.04 0.3144
EPO (N¼7207) 2,183, 30.3% 1.06 1.01 1.12 0.0288
HDHP (N¼9,002) 2,545, 28.3% 0.96 0.91 1.01 0.1166
POS (27,501) 8,258, 30.0% 1.05 1.02 1.09 0.0022
POS capitation (N¼2717) 815, 30.0% 0.98 0.90 1.07 0.6862
PPO (N¼243,531) 71,703, 29.4% 1.04 1.02 1.06 0.0002
HMO (N¼61,079) 17,110, 28.0% Ref.
Type of provider who administered the 1st dose
Pediatric (N¼161,813) 46,344, 28.6% 0.85 0.83 0.87 o .0001
OB/GYN (N¼49,633) 18,006, 36.3% 1.73 1.68 1.78 o .0001
Others (N¼112,855) 31,101, 27.6% 0.99 0.96 1.01 0.3055
Primary care (N¼54,183) 15,835, 29.2% Ref.
Quarter of the year at the 1st dose
Jan–Mar (N¼93,848) 25,894, 27.6% 1.01 0.99 1.04 0.2593
Apr–Jun (N¼93,625) 31,671, 33.8% 1.39 1.35 1.42 o .0001
Jul–Sep (N¼131,567) 36,423, 27.7% 0.99 0.98 1.02 0.9459
Oct–Dec (N¼59,444) 17,298, 29.1% Ref.
Flu vaccination
Yes (N¼135,117) 46,847, 34.7% 1.55 1.52 1.57 o .0001
No (N¼243,367) 64,439, 26.5% Ref.
Abbreviations: HPV: human papillomavirus; MSA: Metropolitan Statistical Area; CDHP: consumer-driven health plan; EPO: Exclusive provider organizations; HDHP: high-
deductible health plan; POS: point of service; PPO: Preferred provider organizations; HMO: Health maintenance organizations; OB/GYN: obstetrics and gynecology; OR: odds
ratio; CI: conﬁdence interval.
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Adherence of HPV vaccine dose schedule was signiﬁcantly
associated with geographic region, health plan, provider type, and
the quarter of the year (1st dose) in a pattern similar to that for
HPV vaccine completion (Table 2). However, in contrast to its
association with HPV vaccine completion, pre-adolescents and
adolescents (o18 years), urban residence, and having ﬂu vacci-
nation was related to signiﬁcantly lower odds of HPV vaccine dose
adherence.Discussion
HPV vaccine completion
Using a large national claims data we found that among com-
mercially insured females who initiated HPV vaccination, only
about 30% had actually completed the 3-dose vaccine series within
12 months during 2009-2011. Even among adolescent girls aged 13
through 15 years, the complete rate was only 29.3%. In other stu-
dies HPV vaccine completion rates widely ranged from 22% to 75%
among HPV vaccine initiators because of different study pop-
ulations, sampling frames and study periods [15,25–31]. Thecompletion rate in our study was comparable with the rate (22%)
observed by Dunne et al. using the same data source [30], but was
much lower than the rates reported from national surveys
[15,25,29]. As we used more strict criteria for selecting the study
cohort and for deﬁning HPV vaccine completion, it is possible that
the completion rate was underestimated in our study if some
females received the 2nd and/or the 3rd dose(s) after 12 months of
initiation. Consistent with previous research, we found that age
was signiﬁcantly associated with HPV vaccine completion; pre-
adolescent girls aged 9–12 years had the highest vaccine dosage
completion rate, while young adult women aged 18–21 had the
lowest rate [27,32]. The age distribution also showed a delay in
initiating HPV vaccination, with only a quarter of vaccinated
females received their ﬁrst doses at age 9–12.
Variation in HPV vaccine completion across health insurance
plans was possibly due to different reimbursement policies for
HPV vaccines. Previous studies have reported that inadequate
insurance reimbursement as a major barrier for providers to offer
HPV vaccination, resulting in a lower vaccine completion rate in
eligible female patients [33–35]. However, in our study we did not
observe signiﬁcant effects of medical expense (total and net costs)
per HPV vaccination on the completion or adherence rate (data
was not shown because of very small differences). We also obs-
erved a great geographic variation in HPV vaccination, particularly
Table 2
HPV vaccine dose adherence rate among 111,286 commercially insured females
who completed the 3-dose HPV vaccine series.
Characteristics HPV vaccine
dose adher-
ence N, %
Multivariable logistic regression model
Adjusted OR 95% Conﬁdence
intervals
P-value
Age group at the 1st dose of HPV vaccination
9–10 (N¼2,416) 1,437, 59.5% 0.75 0.68 0.83 o .0001
11–12 (N¼27,041) 16,233, 60.0% 0.79 0.75 0.84 o .0001
13–15
(N¼32,790)
19,675, 60.0% 0.74 0.70 0.78 o .0001
16–17 (N¼18,741) 11,426,61.0% 0.69 0.65 0.73 o .0001
18–21 (N¼17,667) 11,164,63.2% 0.64 0.61 0.68 o .0001
22–26
(N¼12,631)
9,462, 74.9% Ref.
US census region
Northeast
(N¼19,227)
12,257, 63.8% 1.12 1.08 1.17 o .0001
South (N¼40,307) 25,406, 63.0% 1.02 0.98 1.05 0.2933
West (N¼19,570) 11,800, 60.3% 0.94 0.91 0.98 0.0030
North Central
(N¼32,182)
19,934, 61.2% Ref.
Residence
Urban (MSA)
(N¼98,879)
61,218, 61.9% 0.87 0.84 0.91 o .0001
Rural (non-MSA)
(N¼12,407)
4,228, 65.9% Ref.
Health insurance plan
CDHP (N¼5,291) 3,212, 60.7% 1.01 0.95 1.08 0.7528
Comprehensive
(N¼1,053)
680, 64.6% 1.14 0.99 1.30 0.0513
EPO (N¼2,183) 1,326, 60.7% 1.02 0.92 1.11 0.7423
HDHP (N¼2,545) 1,581, 62.1% 1.07 0.98 1.17 0.1263
POS (N¼8,258) 5,114, 61.9% 1.02 0.96 1.07 0.5530
POS capitation
(N¼815)
527, 64.7% 1.09 0.94 1.27 0.2434
PPO (N¼71,703) 45,030, 62.8% 1.05 1.02 1.09 0.0040
HMO (N¼17,110) 10,469, 61.2% Ref.
Type of provider who administered the 1st dose
Pediatric
(N¼46,344)
26,243, 56.6% 0.74 0.72 0.77 o .0001
OB/GYN
(N¼18,006)
13,207, 73.4% 1.41 1.34 1.48 o .0001
Others
(N¼31,101)
15,755, 63.2% 0.96 0.92 0.99 0.0402
Primary care
(N¼15,835)
10,203, 64.4% Ref.
Quarter of the year at the 1st dose
Jan–Mar
(N¼25,894)
17,429, 67.3% 1.30 1.25 1.36 o .0001
Apr–Jun
(N¼31,671)
20,831, 65.8% 1.26 1.21 1.31 o .0001
Jul–Sep
(N¼36,423)
20,682, 56.8% 0.89 0.86 0.92 o .0001
Oct–Dec
(N¼17,298)
10,455, 60.4% Ref.
Flu shot
Yes (N¼46,847) 27,686, 59.1% 0.92 0.90 0.95 o .0001
No (N¼64,439) 41,711, 64.7% Ref.
Abbreviations: HPV: human papillomavirus; MSA: Metropolitan Statistical Area;
CDHP: consumer-driven health plan; EPO: Exclusive provider organizations; HDHP:
high-deductible health plan; POS: point of service; PPO: Preferred provider orga-
nizations; HMO: Health maintenance organizations; OB/GYN: obstetrics and
gynecology; OR: odds ratio; CI: conﬁdence interval.
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regions. Along with the variation in HPV vaccine completion by
health insurance plan, it was likely that different health insurance
policies across the states may have partly contributed to this
geographic variation in HPV vaccination. Interestingly the com-
pletion rate remains barely over 20% among commercially insured
adolescent girls in Virginia (21.8%) and the District of Columbia
(15.7%), in which HPV vaccination is mandatory for middle school
students [36].When examining the completion rate by provider type, we
found that compared with females who initiated vaccination from
primary care providers, those receiving their ﬁrst doses from OB/
GYN providers were more likely to complete the vaccine series;
while those who received vaccines from pediatricians were sig-
niﬁcantly less likely to complete HPV vaccination [27]. As
numerous studies have concluded that provider recommenda-
tions play an important role in promoting HPV vaccine uptake
[34,35,37–42], OB/GYN providers may have better knowledge and
expertize in HPV-related diseases and HPV vaccination, therefore,
they may be more likely to remind patients to complete their
vaccine series. However, previous studies have found inconsistent
results regarding the association between pediatric providers and
HPV vaccine completion: some studies showed that patients of
pediatric providers were more likely to complete the vaccine than
those of general medicine providers, while some studies indicated
lower HPV vaccine completion in patients seen by pediatricians
[20,26,43].
We used seasonal ﬂu vaccination as an indicator for healthcare-
seeking behavior. As our results showed that females who received
the ﬂu vaccine were more likely to complete HPV vaccine series, it
implies that individual’s behaviors toward preventive health ser-
vices can inﬂuence HPV vaccination [44]. Additionally, providers
may use ﬂu vaccination as an opportunity to encourage patients to
complete their HPV vaccine series. We also observed an interesting
seasonal pattern in HPV vaccine completion: females who initiated
the vaccination during the 2nd quarter of the year (April–June)
were more likely to complete the vaccine series. This seasonal
variation was not due to loss to follow up or changes in health
insurance plans as all females were continuously enrolled for 12
months or longer. It was possible that ﬂu vaccination during
October–December may help physicians or patients to remember
HPV vaccination, but more studies will need to be conducted to
understand factors contributing to this seasonal pattern.
Adherence of recommended HPV vaccine dose schedules
Our study also provided new ﬁndings on the adherence of HPV
vaccine dose schedules. Among females who have completed HPV
vaccination, about 60% (18% in total vaccine-eligible females) have
received the 2nd and 3rd doses no later than 30 days after the
recommended intervals. A delay in the 3rd dose is more common,
possibly because of the prolonged vaccine interval – 6 months
after the ﬁrst dose. Consistent with ﬁndings in HPV vaccine
completion, females who were covered by consumer-driven health
plan (CDHP) or PPO, initiated the vaccination from OB/GYN pro-
viders, or received the 1st dose in the ﬁrst 2 quarters of the year
were more likely to follow the vaccine schedules, while those
receiving HPV vaccination from pediatricians were signiﬁcantly
less likely to complete the vaccine series within the 6-month
interval. Interestingly, unlike in HPV vaccine completion, younger
age (o22 years) and receipt of ﬂu vaccine were negatively related
to adherence of HPV vaccine schedules. These results could be due
to some logistic barriers for younger females or their parents (e.g.,
school attendance, transportation, or inconvenient schedules for
parents), or the possibility that people may wait to combine HPV
vaccine with ﬂu vaccine to reduce the number of visits.
The recommended HPV doses and schedules are based on
immunogenicity and vaccine efﬁcacy from clinical trials. New
evidence suggests that the reduced doses (2-dose vaccines) or
prolonged schedules (at 0 and 12 months) may be as efﬁcient as
the current 3-dose schedules, but would result in lower costs and
better adherence [24,45,46]. While ﬂexible dose schedules could
be important for improving national HPV vaccination, in our study
we detected that a delay for the 3rd dose was common. Thus,
efforts will need to focus on establishing or improving the
G. Liu et al. / Papillomavirus Research 2 (2016) 1–8 7reminding system for HPV vaccination, increasing awareness of
HPV vaccine schedules for patients (or parents of pre- and ado-
lescent girls), and reducing logistic barriers for both patients and
providers [47–49]. Special attention should also be given to
females aged 18–21 as they have lower rates of completion and
adherence of HPV vaccination.
Study limitations
Several caveats need to be discussed when interpreting our
study results. First, although the MarketScan CCE database
annually includes over 50 million people covered by commercial
insurance, the study population is not representative of the US
general population. We also excluded females without at least 12-
month continuous enrollment, those with 43 HPV vaccine claims
or those with HPV vaccine claim(s) in 2008. Therefore, our study
ﬁndings may not be applicable to other populations, especially
underinsured or underserved females. Second, as MarketScan CCE
is a claims database, limited information was available to better
evaluate possible barriers for HPV vaccination. Third, as we
examined HPV vaccine completion within 12 months, we may
miss some females who received HPV vaccine doses over the 12-
month period. That we chose the 12-month period was based on
non-inferiority immunogenicity between the original HPV vaccine
schedule and the alternative vaccine schedule at 0, 6, and 12
months [24]. In addition, we focused on the delayed HPV vaccine
dose schedules as a study outcome and did not assess early HPV
vaccination (i.e., receiving the 2nd and 3rd doses earlier than the
recommended schedules, accounting for about 2% of total eligible
females). Despite of these limitations, our study still provides new
and important results that can be utilized to improve HPV vacci-
nation in the US.
In conclusion, HPV vaccination in the US remains well below
the optimal goal. The reasons for non-completion or non-
adherence of HPV vaccine series are multifactorial. In order to
increase HPV vaccine uptake in the US, intervention programs to
improve HPV vaccine reminding system and reduce logistic bar-
riers for both physicians and patients are warranted.Conﬂict of interest
None reported.Author contribution
GL contributed toward the conception and design of the study,
acquisition and analysis of data, drafting the manuscript and
approving the ﬁnal version. LK contributed toward the design of
the study and analysis of data, drafting the manuscript and
approving the ﬁnal version. PD contributed toward the conception
and design of the study, interpretation of data, drafting the
manuscript, and ﬁnal approval of the version to be submitted.References
[1] C.L. Satterwhite, E. Torrone, E. Meites, E.F. Dunne, R. Mahajan, M.C. Ocfemia,
et al., Sexually transmitted infections among us women and men: prevalence
and incidence estimates, 2008, Sex Transm. Dis. 40 (2013) 187–193.
[2] C. de Martel, J. Ferlay, S. Franceschi, J. Vignat, F. Bray, D. Forman, et al., Global
burden of cancers attributable to infections in 2008: a review and synthetic
analysis, Lancet Oncol. 13 (2012) 607–615.
[3] Centers for Disease Control and Prevention, Human papillomavirus-associated
cancers-United States, 2004–2008, MMWR Morb Mortal Wkly Rep. 61 (2012)
258–261.[4] H.W. Chesson, D.U. Ekwueme, M. Saraiya, M. Watson, D.R. Lowy, L.
E. Markowitz, Estimates of the annual direct medical costs of the prevention
and treatment of disease associated with human papillomavirus in the United
States, Vaccine 30 (2012) 6016–6019.
[5] E. Barr, H.L. Sings, Prophylactic HPV vaccines: new interventions for cancer
control, Vaccine 26 (2008) 6244–6257.
[6] M.A. Kane, Preventing cancer with vaccines: progress in the global control of
cancer, Cancer Prev. Res. (Phila) 5 (2012) 24–29.
[7] G. Van Kriekinge, X. Castellsague, D. Cibula, N. Demarteau, Estimation of the
potential overall impact of human papillomavirus vaccination on cervical
cancer cases and deaths, Vaccine 32 (2014) 733–739.
[8] L.E. Markowitz, E.F. Dunne, M. Saraiya, H.W. Chesson, C.R. Curtis, J. Gee, et al.,
Human papillomavirus vaccination: recommendations of the Advisory Com-
mittee on Immunization Practices (ACIP), MMWR Recomm. Rep. 63 (2014)
1–30.
[9] L.E. Markowitz, S. Hariri, C. Lin, E.F. Dunne, M. Steinau, G. McQuillan, et al.,
Reduction in Human Papillomavirus (HPV) prevalence among young women
following hpv vaccine introduction in the United States, national health and
nutrition examination surveys, 2003–2010, J. Infect. Dis. 208 (2013) 385–393.
[10] J. Gee, A. Naleway, I. Shui, J. Baggs, R. Yin, R. Li, et al., Monitoring the safety of
quadrivalent human papillomavirus vaccine: ﬁndings from the vaccine safety
datalink, Vaccine 29 (2011) 8279–8284.
[11] B.A. Slade, L. Leidel, C. Vellozzi, E.J. Woo, W. Hua, A. Sutherland, et al., Post-
licensure safety surveillance for quadrivalent human papillomavirus recom-
binant vaccine, Jama 302 (2009) 750–757.
[12] U.S. Department of Health and Human Services. Ofﬁce of Disease Prevention
and Health Promotion. Healthy People 2020. Immunization and Infectious
Diseases. IID–11.4 3 doses Human papillomavirus vaccine (HPV) for females by
age 13 to 15 years. In. Washington, DC; 2012.
[13] Stokley S., Jeyarajah J., Yankey D., Cano M., Gee J., Roark J., et al. Human
papillomavirus vaccination coverage among adolescents, 2007-2013, and
postlicensure vaccine safety monitoring, 2006-2014–United States. MMWR
Morb Mortal Wkly Rep. 2014,63:620-624.
[14] W.W. Williams, P.J. Lu, A. O'Halloran, C.B. Bridges, T. Pilishvili, C.M. Hales, et al.,
Noninﬂuenza vaccination coverage among adults-United States, 2012, MMWR
Morb Mortal Wkly Rep. 63 (2014) 95–102.
[15] S. Reagan-Steiner, D. Yankey, J. Jeyarajah, L.D. Elam-Evans, J.A. Singleton, C.
R. Curtis, et al., National, regional, state, and selected local area vaccination
coverage among adolescents aged 13–17 years-United States, 2014, MMWR
Morb Mortal Wkly Rep. 64 (2015) 784–792.
[16] The President’s Cancer Panel. Accelerating HPV Vaccine Uptake: Urgency for
Action to Prevent Cancer. A Report to the President of the United States from
the President’s Cancer Panel. In. Bethesda, MD: National Cancer Institute;
2014.
[17] R.M. Wilson, D.R. Brown, D.P. Carmody, S. Fogarty, HPV vaccination comple-
tion and compliance with recommended dosing intervals among female and
male adolescents in an inner-city community health center, J. Community
Health 40 (2015) 395–403.
[18] C.G. Dorell, S. Stokley, D. Yankey, L.E. Markowitz, Compliance with recom-
mended dosing intervals for HPV vaccination among females, 13–17 years,
National Immunization Survey-Teen, 2008–2009, Vaccine 30 (2012) 503–505.
[19] D.M. Harper, I. Verdenius, G.D. Harris, A.L. Barnett, B.E. Rosemergey, A.M. Arey,
et al., The inﬂuence of free quadrivalent human papillomavirus vaccine (HPV4)
on the timely completion of the three dose series, Prev. Med. 61 (2014) 20–25.
[20] W. Tan, A.J. Viera, B. Rowe-West, A. Grimshaw, B. Quinn, E.B. Walter, The HPV
vaccine: are dosing recommendations being followed? Vaccine 29 (2011)
2548–2554.
[21] I. Verdenius, D.M. Harper, G.D. Harris, R.S. Grifﬁth, J. Wall, L.K. Hempstead,
et al., Predictors of three dose on-time compliance with HPV4 vaccination in a
disadvantaged, underserved, safety net population in the US Midwest, PLoS
One 8 (2013) e71295.
[22] L.E. Widdice, D.I. Bernstein, A.C. Leonard, K.A. Marsolo, J.A. Kahn, Adherence to
the HPV vaccine dosing intervals and factors associated with completion of
3 doses, Pediatrics 127 (2011) 77–84.
[23] Thomson Reuters (Healthcare) Inc. MarketScan Commercial Claims and
Encounters Database and the Medicare Supplemental Database. In.
[24] M.A. Stanley, S.L. Sudenga, A.R. Giuliano, Alternative dosage schedules with
HPV virus-like particle vaccines, Expert Rev. Vaccines 13 (2014) 1027–1038.
[25] M. Rahman, T.H. Laz, C.J. McGrath, A.B. Berenson, Correlates of human papil-
lomavirus vaccine series completion among young adult female initiators,
Hum. Vaccin Immunother 10 (2014) 2163–2167.
[26] C. Chao, C. Velicer, J.M. Slezak, S.J. Jacobsen, Correlates for human papillo-
mavirus vaccination of adolescent girls and young women in a managed care
organization, Am. J. Epidemiol. 171 (2010) 357–367.
[27] J.M. Hirth, A. Tan, G.S. Wilkinson, A.B. Berenson, Completion of the human
papillomavirus vaccine series among insured females between 2006 and
2009, Cancer 118 (2012) 5623–5629.
[28] M.A. Schmidt, R. Gold, S.K. Kurosky, M.F. Daley, S.A. Irving, J. Gee, et al., Uptake,
coverage, and completion of quadrivalent human papillomavirus vaccine in
the vaccine safety Datalink, July 2006–June 2011, J. Adolesc. Health 53 (2013)
637–641.
[29] T.H. Laz, M. Rahman, A.B. Berenson, Human papillomavirus vaccine uptake
among 18- to 26-year-old women in the United States: National Health
Interview Survey, 2010, Cancer 119 (2013) 1386–1392.
G. Liu et al. / Papillomavirus Research 2 (2016) 1–88[30] E.F. Dunne, S. Stokley, W. Chen, F. Zhou, Human papillomavirus vaccination of
females in a large health claims database in the United States, 2006–2012, J.
Adolesc. Health 56 (2015) 408–413.
[31] P. Du, F. Camacho, J. McCall-Hosenfeld, E. Lengerich, C.M. Meyers, N.
D. Christensen, Human papillomavirus vaccination among adults and children
in 5 US States, J. Public Health Manag. Pract. 1 (2015) 1.
[32] R. Gold, A. Naleway, K. Riedlinger, Factors predicting completion of the human
papillomavirus vaccine series, J. Adolesc. Health 52 (2013) 427–432.
[33] J.L. Young, R.G. Bernheim, J.E. Korte, M.H. Stoler, T.M. Guterbock, L.W. Rice,
Human papillomavirus vaccination recommendation may be linked to reim-
bursement: a survey of Virginia family practitioners and gynecologists, J.
Pediatr. Adolesc. Gynecol. 24 (2011) 380–385.
[34] D.M. Holman, V. Benard, K.B. Roland, M. Watson, N. Liddon, S. Stokley, Barriers
to human papillomavirus vaccination among US adolescents: a systematic
review of the literature, JAMA Pediatr. 168 (2014) 76–82.
[35] S.T. Vadaparampil, T.L. Malo, J.A. Kahn, D.A. Salmon, J.H. Lee, G.P. Quinn, et al.,
Physicians' human papillomavirus vaccine recommendations, 2009 and 2011,
Am. J. Prev. Med. 46 (2014) 80–84.
[36] National Conference of State Legislatures. HPV Vaccine: State Legislation and
Statutes. In; 2012.
[37] C.G. Dorell, D. Yankey, T.A. Santibanez, L.E. Markowitz, Human papillomavirus
vaccination series initiation and completion, 2008–2009, Pediatrics 128 (2011)
830–839.
[38] S.L. Rosenthal, T.W. Weiss, G.D. Zimet, L. Ma, M.B. Good, M.D. Vichnin, Pre-
dictors of HPV vaccine uptake among women aged 19–26: importance of a
physician's recommendation, Vaccine 29 (2011) 890–895.
[39] M. Lau, H. Lin, G. Flores, Factors associated with human papillomavirus
vaccine-series initiation and healthcare provider recommendation in US
adolescent females: 2007 National Survey of Children's Health, Vaccine 30
(2012) 3112–3118.
[40] A.N. Polonijo, R.M. Carpiano, Social inequalities in adolescent human papil-
lomavirus (HPV) vaccination: a test of fundamental cause theory, Soc. Sci.
Med. 82 (2013) 115–125.[41] K.R. Ylitalo, H. Lee, N.K. Mehta, Health care provider recommendation, human
papillomavirus vaccination, and race/ethnicity in the US National Immuniza-
tion Survey, Am. J. Public Health 103 (2013) 164–169.
[42] M. Rahman, T.H. Laz, C.J. McGrath, A.B. Berenson, Provider recommendation
mediates the relationship between parental human papillomavirus (HPV)
vaccine awareness and HPV vaccine initiation and completion among 13- to
17-year-old U.S. adolescent children, Clin. Pediatr. (Phila) 54 (2015) 371–375.
[43] J. Shen-Gunther, J.J. Shank, V. Ta, H.P.V. Gardasil, vaccination: surveillance of
vaccine usage and adherence in a military population, Gynecol. Oncol. 123
(2011) 272–277.
[44] T.H. Laz, M. Rahman, A.B. Berenson, An update on human papillomavirus
vaccine uptake among 11–17 year old girls in the United States: National
Health Interview Survey, 2010, Vaccine 30 (2012) 3534–3540.
[45] B. Romanowski, T.F. Schwarz, L.M. Ferguson, M. Ferguson, K. Peters, M. Dionne,
et al., Immune response to the HPV-16/18 AS04-adjuvanted vaccine admi-
nistered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results
from a randomized study, Hum. Vaccin. Immunother 10 (2014) 1155–1165.
[46] E. Lazcano-Ponce, M. Stanley, N. Munoz, L. Torres, A. Cruz-Valdez, J. Salmeron,
et al., Overcoming barriers to HPV vaccination: non-inferiority of antibody
response to human papillomavirus 16/18 vaccine in adolescents vaccinated
with a two-dose vs. a three-dose schedule at 21 months, Vaccine 32 (2014)
725–732.
[47] A. Patel, L. Stern, Z. Unger, E. Debevec, A. Roston, R. Hanover, et al., Staying on
track: a cluster randomized controlled trial of automated reminders aimed at
increasing human papillomavirus vaccine completion, Vaccine 32 (2014)
2428–2433.
[48] D.J. Etter, G.D. Zimet, V.I. Rickert, Human papillomavirus vaccine in adolescent
women: a 2012 update, Curr. Opin. Obstet Gynecol. 24 (2012) 305–310.
[49] B. Cassidy, B. Braxter, D. Charron-Prochownik, E.A. Schlenk, A quality
improvement initiative to increase HPV vaccine rates using an educational and
reminder strategy with parents of preteen girls, J. Pediatr. Health Care 28
(2014) 155–164.
